Naltrexone and Vivitrol in Addiction Treatment: Uses and Eligibility

Naltrexone is an opioid antagonist medication approved by the U.S. Food and Drug Administration (FDA) for treating both opioid use disorder and alcohol use disorder. It is available in two distinct formulations: a daily oral tablet and an extended-release injectable suspension marketed under the brand name Vivitrol. This page covers the pharmacological mechanism, clinical eligibility criteria, contrasts between formulations, and the decision thresholds that govern clinical use — drawing on FDA labeling, SAMHSA guidelines, and ASAM criteria.

Definition and Scope

Naltrexone belongs to the opioid antagonist class of medications, distinguishable from partial agonists such as buprenorphine and full agonists such as methadone. Unlike those agents, naltrexone produces no opioid effect and carries no federal scheduling designation under the Controlled Substances Act (DEA Drug Scheduling, 21 U.S.C. § 812), as amended by legislation effective December 23, 2024, which corrected a technical error in the Act's definitions. This amendment does not alter naltrexone's unscheduled status or the prescribing requirements applicable to it. This means prescribing naltrexone does not require a DEA waiver or a specialized clinic registration, which historically lowered the administrative barrier to prescribing compared to methadone or buprenorphine.

The FDA first approved oral naltrexone (50 mg tablet, brand name Revia) for opioid dependence in 1984 and for alcohol dependence in 1994 (FDA Drug Approvals and Databases). Vivitrol — extended-release naltrexone injectable (380 mg intramuscular, monthly) — received FDA approval for alcohol use disorder in 2006 and for opioid use disorder in 2010. Within the broader landscape of medication-assisted treatment, naltrexone occupies a distinct niche as a non-addictive, non-scheduled pharmacotherapy.

The scope of naltrexone use in addiction medicine is defined at the federal level by FDA labeling and at the clinical practice level by the American Society of Addiction Medicine (ASAM) and SAMHSA's Treatment Improvement Protocols (TIPs), particularly TIP 63: Medications for Opioid Use Disorder.

How It Works

Naltrexone acts as a competitive antagonist at mu, kappa, and delta opioid receptors in the central nervous system. By occupying these receptor sites without activating them, naltrexone blocks the euphoric and analgesic effects of exogenous opioids. A standard oral dose of 50 mg blocks the effects of 25 mg of intravenous heroin for approximately 24 hours; higher doses extend this blockade (SAMHSA TIP 63).

In alcohol use disorder, the mechanism is distinct. Alcohol stimulates endogenous opioid peptide release, which contributes to reinforcement. Naltrexone attenuates this reward pathway, reducing craving and the incentive to drink after a lapse. Clinical trials underpinning the FDA alcohol approval demonstrated reductions in heavy drinking days, with the pivotal trial (the COMBINE study, published in JAMA 2006) finding that naltrexone combined with medical management reduced the rate of heavy drinking days compared to placebo (NIAAA COMBINE Study).

The pharmacokinetic distinction between formulations is clinically significant:

1. Oral naltrexone (50 mg/day): Peak plasma concentration reached within 1 hour; half-life approximately 4 hours for naltrexone, with the active metabolite 6-beta-naltrexol extending effect to roughly 13 hours. Adherence is entirely patient-dependent.
2. Extended-release injectable (Vivitrol, 380 mg IM monthly): Produces sustained plasma concentrations over 28–30 days following a single gluteal injection, eliminating daily adherence decisions. Peak plasma concentration occurs at approximately 2 hours post-injection with a sustained plateau.

This pharmacokinetic difference is the primary driver of formulation selection in settings where adherence risk is a treatment-planning concern, particularly relevant to discussions of levels of care using ASAM criteria.

Common Scenarios

Naltrexone and Vivitrol appear across a range of treatment contexts within the addiction care continuum. The following structured breakdown reflects the principal clinical scenarios documented in SAMHSA and ASAM literature:

1. Post-detoxification maintenance for opioid use disorder: Naltrexone is initiated after a minimum opioid-free interval (typically 7–10 days for short-acting opioids; 10–14 days for methadone) to avoid precipitated withdrawal. It is used in patients who have completed detox services and prefer a non-opioid pharmacotherapy.
2. Alcohol use disorder outpatient treatment: Prescribed in outpatient rehab settings alongside behavioral interventions such as cognitive behavioral therapy or motivational enhancement therapy.
3. Criminal justice and supervised populations: Vivitrol's monthly dosing makes it logistically suited to individuals transitioning from incarceration or under court supervision, where daily medication administration is not guaranteed.
4. Patients with co-occurring disorders: In individuals with co-occurring psychiatric conditions, naltrexone carries no abuse potential, which simplifies polypharmacy risk management compared to scheduled agents.
5. Partial hospitalization and intensive outpatient programs: Naltrexone initiation frequently occurs within partial hospitalization programs where medical supervision supports the transition off opioids before dosing begins.
6. Veterans populations: The U.S. Department of Veterans Affairs (VA) includes naltrexone in its formulary for both alcohol and opioid use disorder, relevant to veterans drug rehab programs.

Decision Boundaries

Clinical eligibility for naltrexone is defined by contraindications, mandatory preconditions, and formulation-specific considerations established in FDA labeling and ASAM clinical practice guidelines.

Absolute contraindications (per FDA labeling):
- Current physiological opioid dependence (risk of precipitated withdrawal)
- Acute opioid withdrawal
- Failed naloxone challenge test
- Acute hepatitis or liver failure
- Hypersensitivity to naltrexone, polylactide-co-glycolide, carboxymethylcellulose, or any component of the Vivitrol formulation

Preconditions for initiation:
- Opioid-free period: minimum 7–10 days (short-acting opioids), 10–14 days (long-acting opioids/methadone), confirmed by urine toxicology
- Liver function assessment: naltrexone carries an FDA boxed warning for hepatotoxicity at supratherapeutic doses; baseline liver enzymes (AST, ALT) are assessed prior to initiation (FDA Vivitrol Prescribing Information)
- Naloxone challenge (optional but recommended when opioid abstinence cannot be confirmed)

Oral vs. injectable formulation decision framework:

ASAM's National Practice Guideline for the Treatment of Opioid Use Disorder specifies that patient preference, adherence history, and treatment setting are primary variables in formulation selection — not one formulation's pharmacological superiority over the other for all patients (ASAM National Practice Guideline, 2020).

Naltrexone's unscheduled status under the Controlled Substances Act reflects its classification as a non-addictive opioid antagonist. Legislation effective December 23, 2024, amended the Controlled Substances Act to correct a technical error in the Act's definitions; this amendment does not alter naltrexone's unscheduled status or the prescribing requirements applicable to it. Clinicians should confirm current DEA guidance if questions arise regarding how the definitional correction interacts with specific scheduling determinations.

Naltrexone does not address the full scope of substance use disorder diagnosis needs and is pharmacologically inactive against stimulants, benzodiazepines, and cannabis — a boundary that limits its role to opioid and alcohol pathways specifically. For opioid use disorder, the comparative pharmacotherapy landscape also includes buprenorphine/Suboxone treatment and methadone treatment clinics, each governed by distinct regulatory frameworks and eligibility criteria.

References

• FDA Drug Approvals and Databases — Naltrexone/Revia/Vivitrol
• FDA Vivitrol (Naltrexone Extended-Release Injectable) Prescribing Information
• SAMHSA Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder
• DEA Drug Scheduling, 21 U.S.C. § 812 — as amended December 23, 2024, to correct a technical error in the Controlled Substances Act definitions; this amendment does not alter naltrexone's unscheduled status